Australian psychiatrists push for Medicare to subsidise ketamine for treatment-resistant depression
by Melissa Davey Medical editor from World news | The Guardian on (#6CZ2K)
Application for subsidy follows results of a groundbreaking study into severe depression
Researchers supported by Australia's peak body for psychiatrists have applied to have ketamine treatments for depression subsidised by Medicare, following the results of a trial which found a low-cost version of the drug can treat severe depression.
Currently, S-ketamine nasal spray is sometimes prescribed in Australia for treatment-resistant depression, but it costs approximately $800 per dose, and combined with the consultation cost, patients can pay around $1,150 for treatment.
Sign up for Guardian Australia's free morning and afternoon email newsletters for your daily news roundup
Continue reading...